HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024Business Wire • 08/12/24
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024PRNewsWire • 08/11/24
25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability NetworkBusiness Wire • 08/06/24
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024Business Wire • 08/06/24
Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024Business Wire • 07/29/24
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of IvonescimabBusiness Wire • 07/25/24
Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of DirectorsBusiness Wire • 06/27/24
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall StreetThe Motley Fool • 06/17/24
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMABusiness Wire • 06/01/24
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus ChemotherapyBusiness Wire • 05/31/24
Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbusterMarket Watch • 05/30/24
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in ChinaBusiness Wire • 05/30/24
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To CancerSeeking Alpha • 05/06/24
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024Business Wire • 05/01/24